 SOUTH SAN FRANCISCO--BUSINESS WIRE--VistaGen Therapeutics, Inc. Nasdaq: VTGN VistaGen, a late clinical-stage, central nervous system CNS-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced that the clinical trial abstract for its exploratory Phase 2A clinical study in adjustment disorder with anxiety AjDA for PH94B, its investigational rapid-onset pherine nasal spray with 